4/A: Fairmount Funds Management Amends Form 4 Filing for Zenas BioPharma Following IPO
SEC Filing (Form 4/A)
Fairmount Funds Management LLC files an amended Form 4 to correct previously reported amounts of securities beneficially owned following Zenas BioPharma's IPO and the conversion of preferred stock to common stock.
Summary
- Fairmount Funds Management LLC filed an amended Form 4 with the SEC on September 17, 2024, related to its holdings in Zenas BioPharma, Inc. (ZBIO).
- The amendment corrects the 'Amount of Securities Beneficially Owned Following Reported Transactions' previously reported in the original Form 4 filed on September 16, 2024.
- The filing reflects the automatic conversion of Series Seed, A, B, and C Convertible Preferred Stock into common stock at a ratio of 8.6831-for-1 upon the closing of Zenas BioPharma's initial public offering (IPO) on September 16, 2024.
- Fairmount Healthcare Fund II LP is the direct holder of the securities, with Fairmount Funds Management LLC acting as its investment manager.
- Tomas Kiselak and Peter Harwin, as managing members of Fairmount Funds Management GP LLC (the general partner of Fairmount), disclaim beneficial ownership except to the extent of their pecuniary interest.
- Tomas Kiselak also acquired 37,000 stock options on September 12, 2024, at an exercise price of $17, vesting annually over three years, but disclaims beneficial ownership as he holds the option for a Fairmount Fund.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, but the correction of previously reported information and the conversion of preferred stock to common stock are positive developments that simplify the company's capital structure. The sentiment is neutral to slightly positive.
Positives
- The conversion of preferred stock to common stock simplifies the capital structure of Zenas BioPharma following its IPO.
- The increased holdings of common stock by Fairmount Healthcare Fund II LP demonstrate continued investment in Zenas BioPharma.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders, particularly after significant events like an IPO. This filing provides transparency into the holdings of major shareholders and their investment activity in the company.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency of insider transactions.
- The conversion of preferred stock to common stock upon an IPO is a common practice to simplify the capital structure and align the interests of all shareholders.
- Investment firms like Fairmount Funds Management routinely file such forms to disclose their holdings and transactions in portfolio companies.
Stakeholder Impact
- Shareholders benefit from increased transparency regarding insider holdings.
- The conversion of preferred stock to common stock simplifies the capital structure, potentially making the company more attractive to investors.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Tomas Kiselak acquired 37,000 stock options. |
| 09/16/2024 | Date of the original Form 4 filing and the closing of Zenas BioPharma's IPO, triggering the automatic conversion of preferred stock to common stock. |
| 09/16/2024 | Conversion of Series Seed Convertible Preferred Stock into 41,130 shares of Common Stock. |
| 09/16/2024 | Conversion of Series A Convertible Preferred Stock into 252,890 shares of Common Stock. |
| 09/16/2024 | Conversion of Series B Convertible Preferred Stock into 709,794 shares of Common Stock. |
| 09/16/2024 | Conversion of Series C Convertible Preferred Stock into 301,077 shares of Common Stock. |
| 09/17/2024 | Date of the amended Form 4/A filing. |
| 09/12/2025 | First anniversary of the vesting commencement date for Tomas Kiselak's stock options. |
| 09/11/2034 | Expiration date of Tomas Kiselak's stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.